Clinical-Stage Neurodegenerative Disease Company Files for $86 Million IPO

Cortexyme has filed for an $86 million IPO. The company is developing treatments for neurodegenerative diseases based on the discovery of pathogenic bacteria in the brains of Alzheimer's patients. Cortexyme intends to trade on the NASDAQ market under the symbol “CRTX.”